semaglutide clinical trials near me AHA 2024: continues to impress in diabetic kidney disease Semaglutide, heavy drinking days and

doi:10.1136/bmj.q1448 Whitley HP, Trujillo JM, Neumiller JJ

Conversely, someone closer to goal weight may need 4-6 weeks before noticing meaningful change

Key Findings: Most common: Nausea (43%), diarrhea (33%), vomiting (21%) Unique to retatrutide: Dysesthesia (20.9% @ 12mg in TRIUMPH-4, 8.8% @ 9mg) Discontinuation rate: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 (general obesity population) compared to semaglutide 6.9%, tirzepatide 6.2% Good news: Most side effects peak during dose escalation and improve significantly after week 16 Management: Slow titration, dietary modifications, and proper timing dramatically reduce severity Understanding the Three Categories of Side Effects 1

never mix the products

Common adverse effects include nausea, vomiting, diarrhoea , and injection site reactions, which typically diminish with continued use

Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]